About Syndax
Syndax is a publicly listed company based in Waltham (United States) founded in 2005. Targeted therapies for cancer treatment are developed. Syndax has raised $198.29 million across 11 funding rounds from investors including Fidelity Investments, Orbimed and ArrowMark Partners. The company has 270 employees. Its website syndax.com draws about 12 thousand monthly visits. Syndax offers products and services including Revumenib and Axatilimab. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include C4 Therapeutics, Erasca and MiRagen; 3 of its 3 listed competitors have raised funding.
Company details
Syndax was founded in 2005 and is headquartered in Waltham, United States. Operations are centered in the biotechnology sector, where targeted therapies for oncology are advanced. Entinostat is being developed as a combination treatment for various cancer types, with primary attention given to immunotherapy-responsive tumors such as those in lung cancer, melanoma, and triple-negative breast cancer.
- Headquarters Waltham, United States
- Employees 270
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website syndax.com
- Social LinkedIn X
- Legal Name Syndax Pharmaceuticals, Inc.
- Annual Revenue$172.35 M (USD)627.84as on Dec 31, 2025
- Net Profit-$285.42 M (USD)10.46as on Dec 31, 2025
- EBITDA-$273.08 M (USD)19.6as on Dec 31, 2025
- Total Equity Funding$198.29M (USD)
in 11 rounds
- Latest Funding Round$35M (USD), Post-IPO
Jan 2020
- InvestorsFidelity Investments
& 14 more
- Employee Count270
Products & Services of Syndax
Syndax offers a comprehensive portfolio of products and services, including Revumenib and Axatilimab.
Investigates treatments for acute leukemias and genetic mutations.
Targets graft-versus-host disease and pulmonary fibrosis conditions.
Funding Insights of Syndax
Syndax has successfully raised a total of $198.29M across 11 strategic funding rounds. The most recent funding activity was a Post-IPO round of $35 million completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $198.29M
- Total Rounds 11
- Last Round Post-IPO — $35M
- First Round $40M
(Apr 2007)
- Investors Count 15
Latest 10 of 11 funding rounds of Syndax with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2020 | $35M | Post-IPO | – | – | – |
| Aug 2015 | $80M | Series C | – | Fidelity Investments, Delos Capital Partners | |
| Jun 2015 | $23.96M | Series B | – | – | – |
| Sep 2014 | $4.95M | Series B | – | – | – |
| Feb 2014 | $1.73M | Series B | – | – | – |
| Jan 2014 | $1.27M | Series B | – | – | – |
| Nov 2013 | $50,000 | Series B | – | – | – |
| Aug 2013 | $31.33M | Series B | – | RusnanoMedInvest | |
| Aug 2010 | $6.01M | Series A | – | Domain Associates, MPM Capital | – |
| Feb 2010 | $9M | Series A | – | – | – |
15 investors in total: 15 institutional.
Investors in Syndax
Syndax has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, Orbimed and ArrowMark Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Life science & tech focused VC firm investing in the US | domainvc.com | Princeton, United States | ||
Life Sciences focused VC firm that does early stage investments in the US | forwardventures.com | San Diego, United States | ||
Healthcare investments are managed by corporate-backed venture capital fund RusnanoMedInvest. | rmi.com.ru | Moscow, Russia | ||
Venture capital investments are directed toward therapeutics and medtech startups. | deloscapital.com | Hong Kong, China | ||
Biotech startups are funded by this venture capital firm. | boxercap.com | San Diego, United States | ||
Early to mid stage life sciences-focused VC firm investing in geographies such as Europe | biomedvc.com | Basel, Switzerland | ||
Seed and early-stage venture capital is provided to US companies. | avalon-ventures.com | Cambridge, United States | ||
VC firm focusing on life science sector | pappas-capital.com | Durham, United States | ||
| ecor1cap.com |
Investor details for Syndax
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Syndax
72 people are tracked at Syndax (58 in leadership, 6 in board & advisors, 8 in team); the tracked headcount is 270.
| Name | Role | Group |
|---|---|---|
Peter Ordentlich | Chief Scientific Officer and Founder | Leadership |
Purvi Patel | Associate Director, Medical Information/communications | Leadership |
Jess Clement | Senior Medical Director | Leadership |
Angela Smith | Executive Medical Director | Leadership |
Anthony S. Zembillas | Senior Regional Director - Msls (east) | Leadership |
Shawn Arend | Director, Leadership Development & Training | Leadership |
Anjali Ganguli | Chief Business Officer | Leadership |
Patricia Catlow | Sr. Director, Alliance And Program Management | Leadership |
Jennifer Taing | Associate Director, Medical Information And Communications | Leadership |
Tom Goins | Regional Business Director | Leadership |
Michelle Moore | Director, Health Outcomes Liaison | Leadership |
Jeff Crowther | Vice President | VP | Marketing | Sales | Training | Leadership |
Jai Yadlapalli | Associate Director, CMC Analytical | Leadership |
Lisa MacKie | Director Of Legal Affairs | Leadership |
Joe Flisak | Senior Director Small Molecule Drug Substance/cmc | Leadership |
Enoch Cobbina | Director Of Clinical Pharmacology & Pharmacometrician (oncology) | Leadership |
Kevin McManus | Chief People Officer | Leadership |
Michael A. Metzger | CEO | Leadership |
Keith A. Goldan | CFO | Leadership |
Steven Closter | Chief Commercial Officer (cco) | Leadership |
52 more people are available in the full profile.
Complete people profiles for Syndax
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Syndax
Syndax is a publicly listed company on the NASDAQ with ticker symbol SNDX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date03 Mar 2016
- Listed onNASDAQ: SNDX
- Listed entitySyndax Pharmaceuticals, Inc.
- Exchange sectorHealth technology
- ISINUS87164F1057
- Share price$13.95 (-15.71% on the day) · 2026-10-13
- Market capitalisation$1.25B
- EPS (diluted, trailing year)$-2.52
- Volume (last session)6,808,603
Financials of Syndax
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $172.3M | -$285.4M | -$273.1M |
| 2024 | $23.7M | -$318.8M | -$339.7M |
| 2023 | -$209.4M | -$229.9M | |
| 2022 | -$149.3M | -$151.3M | |
| 2021 | $139.7M | $24.9M | $26.7M |
Detailed financial statements for Syndax
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Syndax
4 dated milestones of Syndax across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Syndax is founded.
- Funding First funding round of $40.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $35.0M.
Competitors of Syndax
Syndax has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and MiRagen.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. |
Detailed competitors of Syndax
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Syndax
The website of Syndax (syndax.com) receives about 12.2K visits a month and ranks #1,539,978 among all websites worldwide, #2,039 in Biotechnology and Pharmaceuticals.
- Monthly visits12.2K
▼ 19.4% vs previous month
- Unique visitors7K
per month
- Global rank#1,539,978
among all websites
- Category rank#2,039
Health · Biotechnology and Pharmaceuticals
- Bounce rate46%
- Pages per visit2.2
- Average visit17 sec
- DevicesDesktop 43% · Mobile 57%
Websites whose visitors overlap most with Syndax. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| visterrainc.com | 100% | 2.5K | #6,988,741 | View details | |
| epicsciences.com | 92% | 35.3K | #589,878 | View details | |
| erytech.com | 91% | View details | |||
| titanpharm.com | 90% | 4.3K | #4,063,501 | View details | |
| biocentury.com | 89% | 85.7K | #514,907 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 14 similar websites and full traffic analytics for Syndax
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 14 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Syndax (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Syndax
Complete news archive for Syndax
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Syndax
Syndax was founded in 2005 and raised its 1st funding round 2 years after it was founded.
Syndax is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Syndax is a funded company, having raised a total of $198.29M across 11 funding rounds to date. The company's 1st funding round was a Series A of $9M, raised on Apr 2007.
Syndax has 270 employees.
Annual revenue of Syndax is $172.35M as on Dec 31, 2025.
Syndax was founded in 2005 and is headquartered in Waltham, United States. Operations are centered in the biotechnology sector, where targeted therapies for oncology are advanced. Entinostat is being developed as a combination treatment for various cancer types, with primary attention given to immunotherapy-responsive tumors such as those in lung cancer, melanoma, and triple-negative breast cancer.
Syndax's top competitors include C4 Therapeutics, Erasca and MiRagen.
Syndax offers Revumenib and Axatilimab.
Yes, Syndax is publicly traded on NASDAQ under the ticker symbol SNDX.
Syndax has 15 investors. Key investors include Fidelity Investments, Orbimed, ArrowMark Partners, EcoR1, and Jennison Associates.